Table 2. Univariate and multivariate analyses of overall survival in patients with malignant pleural mesothelioma.
| Univariate analysis | Multivariate analysis | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Variable | Reference | Hazard ratio | p value | 95% CI | Hazard ratio | p value | 95% CI | ||
| P/D | EPP | 0.48 | 0.11 | 0.16 | 1.17 | ||||
| Age ≥65 years | Age <65 years | 0.92 | 0.83 | 0.43 | 2.04 | ||||
| Male | Female | 0.44 | 0.10 | 0.19 | 1.21 | ||||
| Epithelioid | Others | 0.62 | 0.21 | 0.30 | 1.33 | ||||
| Stage I + II | Stage III | 0.54 | 0.18 | 0.20 | 1.30 | ||||
| CCI 0 | CCI ≥1 | 0.58 | 0.21 | 0.27 | 1.38 | ||||
| GPS 0 | GPS ≥1 | 0.61 | 0.20 | 0.29 | 1.31 | ||||
| NLR <2.8 | NLR ≥2.8 | 0.56 | 0.15 | 0.25 | 1.23 | ||||
| PLR <98 | PLR ≥98 | 0.34 | 0.009* | 0.14 | 0.77 | 0.43 | 0.06 | 0.98 | 6.08 |
| EORTC score <1.13 | EORTC score ≥1.13 | 0.37 | 0.016* | 0.17 | 0.83 | 0.52 | 0.13 | 0.22 | 1.21 |
| Trimodal therapy | No trimodal therapy | 1.25 | 0.55 | 0.60 | 2.63 | ||||
*Statistically significant. CI: confidence interval; P/D: pleurectomy/decortication; EPP: extrapleural pneumonectomy; Others: other types of histology such as biphasic and sarcomatoid; CCI: Charlson comorbidity index; GPS: Glasgow prognostic score; NLR: neutrophil/lymphocyte ratio; PLR: platelet/lymphocyte ratio; EORTC: European Organization for Research and Treatment of Cancer